Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116406202 | 11640620 | 2 | F | 20160209 | 20160714 | 20151019 | 20160727 | EXP | GR-INCYTE CORPORATION-2015IN005186 | INCYTE | 73.00 | YR | M | Y | 0.00000 | 20160727 | MD | GR | GR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116406202 | 11640620 | 1 | PS | JAKAFI | RUXOLITINIB | 1 | Unknown | 5 MG, BID (2X2/DAY) | 202192 | TABLET | |||||||||
| 116406202 | 11640620 | 2 | SS | SINTROM | ACENOCOUMAROL | 1 | Unknown | UNK UNK, QD | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 116406202 | 11640620 | 1 | Polycythaemia |
| 116406202 | 11640620 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 116406202 | 11640620 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 116406202 | 11640620 | Anaemia | |
| 116406202 | 11640620 | Haematocrit decreased | |
| 116406202 | 11640620 | Prostate cancer | |
| 116406202 | 11640620 | Second primary malignancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 116406202 | 11640620 | 1 | 20150805 | 0 |